Camurus Shares Drop After FDA Issues Complete Response Letter for Oclaiz
Camurus AB shares fell sharply after the U.S. Food and Drug Administration issued a Complete Response Letter for Oclaiz (CAM2029) on the PDUFA action date. The agency cited manufacturing observations at a third-party facility and requested a minor labeling change, rather than raising clinical safety or efficacy concerns. Jefferies now expects U.S. …